



Company Presentation

July 2017




ENDOMEDICA

AMW - A Specialty Pharmaceuticals Developer and Manufacturer

- Founded in 2008
- Located in Warngau, Germany, 40 km south of Munich
- Approx. 100 employees, thereof 11 trainees
- Focus on advanced drug delivery systems, e. g. transdermal and transmucosal delivery systems (passive and active control) and parenteral (intracranial, subcutaneous, ...) biodegradable delivery systems
- Core areas: hormone and pain therapy, oncology and neurology
- Funded by private and institutional investors, founders and management, approx. 33% each



Manufacturing Patches



Market Perspectives:

- Worldwide transdermal delivery market is expected to reach more than *40 billion US\$ in 2018* ⁽¹⁾
- There is only a **very limited number of players** in the market being able to develop and manufacture these transdermal products

Production Facility of AMW GmbH:

- clean-room environment Class D* with capacity for industrial mass production
- sufficient space for future expansion at the Warngau site

(1) <http://www.americanpharmaceuticalreview.com/Featured-Articles/169470-Status-Quo-Challenges-and-Opportunities-of-Transdermal-Drug-Delivery/>



Encapsulated Coating Line



Rotary Die Cutting and Packaging Line



Manufacturing Biodegradable Implants

Market Perspectives:

- Worldwide biodegradable drug delivery implant market was 11.6 billion US\$ in 2011 and is expected to exceed *21 billion US\$ by 2018* ⁽²⁾
- AMW is the second biggest manufacturer of these implants worldwide and so far the only manufacturer of generic Goserelin implants

Production Facility of AMW GmbH:

- clean-room environment Class C with capacity for industrial mass production up to 400.000 per year
- sufficient space for future expansion at the Warngau site with new production plant - Expansion of production site midst of 2017 -

(2) <http://www.transparencymarketresearch.com/pressrelease/implantable-drug-delivery-devices.htm>



Strand Measurement and Cutting



Injector Filling

Certifications

- ✓ Manufacturing Authorization for transdermal systems and implants with active substances
- ✓ GMP Certificate
- ✓ Certified in accordance with DIN EN ISO 13485 for medical devices
- ✓ Permission for handling narcotic substances




Main Areas of Activity

Approved products:
Buprenorphine and
Rivastigmin patches

under development:
Rotigotine and
Anastrozole patches

Approved products:
Goserelin
biodegradable
implants

under development:
Leuprorelin,
Exenatide, and MAB
implants



Customized products, i.e. fertility control patch, hypertension patch, scar patch

Endomedica GmbH - R&D -





- since 2014 Endomedica GmbH in Halle/Saale (Saxonia-Anhalt)
- subsidiary of AMW GmbH
- Research and Development (R&D) of medicinal products and medical devices for transdermal application
- Permission for handling narcotic substances
- new laboratory capacities since 2016



Active Release Transdermal Patch

- Currently exclusively focussed on the development of electronically controlled transdermal patch
 - Patented technology
 - Feasibility study successfully completed
 - Pilot study planned for 2017
 - alternative transdermal system instead of iontophoretic patch without painful side effects of skin irritation



Endomedica GmbH - R&D -



- Existing Cooperations:



Fraunhofer Institute for Microelectronic Circuits and Systems; Duisburg



Fraunhofer Institute for Electronic Nano Systems; Chemnitz



Renata SA; Itingen / Switzerland

- Target Cooperation:



Fraunhofer-Institute for Material and Beam Technology; Dresden

Contact



ENDOMEDICA

Research & Development:

Dr. Wilfried Fischer
Managing Director

Business Development:

Thomas Ohlenbostel
Head of BD
t.ohlenbostel@a-m-w.eu
Tel.: +49 8024 470 999 80

Dr. Sebastian Luci
Endomedica GmbH
Weinbergweg 23
D-06120 Halle/Saale
Tel: +49(0)345/13142760 / -61
E-Mail: info@endomedica.de

www.endomedica.de

www.a-m-w.eu/en/